BioXcel Therapeutics Inc (BTAI) stock has risen 910.00% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives BTAI stock a score of 68 out of a possible 100.
That rank is primarily influenced by a fundamental score of 85. In addition to the average rating from Wall Street analysts, BTAI stock has a mean target price of 114.25. This means analysts expect the stock to add 157.09% over the next 12 months. BTAI's rank also includes a short-term technical score of 84. The long-term technical score for BTAI is 35.
What's Happening with BTAI Stock Today
BioXcel Therapeutics Inc (BTAI) stock is lower by -7.59% while the S&P 500 is lower by -2.68% as of 11:33 AM on Wednesday, Oct 28. BTAI is lower by -$3.65 from the previous closing price of $48.09 on volume of 263,177 shares. Over the past year the S&P 500 has risen 8.66% while BTAI has risen 910.00%. BTAI lost -$2.87 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on BioXcel Therapeutics Inc (BTAI) Stock.
